Why the study?
Polypharmacy is usually viewed pejoratively and avoided to optimize functional status, despite some evidence-based regimens reducing disability while others have unclear benefit.
This review proposes a nuanced categorization of polypharmacy in older adults to distinguish between beneficial, harmful, and uncertain medication regimens, aiming to optimize functional status and prevent disability.
Offers a conceptual framework to guide deprescribing in older adults; leaves open the clinical impact of this categorization.
The term polypharmacy in older adults is generally used in a pejorative context in the medical literature. Because of its link to geriatric syndromes and disability, the avoidance of polypharmacy is usually recommended in older adults as a strategy to optimize functional status. However, there are many polypharmacy regimens based on high-quality trials that clearly reduce the risk of disability in older adults. Other guidelines for older adults recommend the use of additional medications that may or may not be evidence based and that may or may not reduce disability. Therefore, we propose that, in the geriatric literature, polypharmacy now be categorized as "necessary polypharmacy," "unnecessary polypharmacy," or "polypharmacy of unclear benefit." In this article, we discuss the 3 categories of polypharmacy and give examples on each polypharmacy regimen and its potential relationship to disability in older adults.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: